Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Advances in Therapy - Tập 30 Số 10 - Trang 870-884 - 2013
Denise A. Yardley1, Shinzaburo Noguchi2, Kathleen I. Pritchard3, Howard A. Burris1, José Baselga4, Michael Gnant5, Gabriel N. Hortobágyi6, Mario Campone7, Barbara Pistilli8, Martine Piccart9, Bohuslav Melichar10, Katarína Petráková11, Francis P. Arena12, Frans Erdkamp13, Wael A. Harb14, Wentao Feng15, Ayelet Cahana15, Tetiana Taran15, David Lebwohl15, Hope S. Rugo16
1Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, 37203, USA
2Department of Breast and Endocrine Surgery, Osaka University, Suita, Osaka, 565-0871, Japan
3Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, ON, M4N 3M5, Canada
4Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
5Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, 1090, Vienna, Austria
6The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
7Institut de Cancérologie de l’Ouest, René Gauducheau, Centre de Recherche en Cancérologie, 44805, Nantes Saint Herblain, France
8Department of Medical Oncology, Ospedale di Macerata, 62100, Macerata, Italy
9Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium
10Department of Oncology, Palacky University Medical School and Teaching Hospital, 775 20, Olomouc, Czech Republic
11Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
12NYU Langone Arena Oncology, P.C., Lake Success, NY, 11042, USA
13Department of Medical Oncology, Orbis Medical Center, 6162 BG, Sittard-Geleen, The Netherlands
14Horizon Oncology, Lafayette, IN, 47905, USA
15Novartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA
16UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94115, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688–94, 696.

National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology: breast cancer, Version 2.2011. http://www.nccn.org/patients/guidelines/breast/index.html (accessed October 7, 2013).

Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23):3784–96.

Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21(3):242–52.

Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643–58.

Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664–70.

Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600.

Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14(10):989–98.

Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367(5):435–44.

Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30(16):1919–25.

Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010;120(7):2406–13.

Klein P, Ordentlich P, McCulloch W, Cruickshank S, Rees M, Yardley DA. Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer [abstract]. J Clin Oncol. 2012;30(Suppl):Abstract 567.

Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718–24.

Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–7.

Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11(14):5319–28.

Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 published August 9, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed October 7, 2013).

Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659–63.

Beck JT, Rugo HS, Burris HA, et al. BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane [abstract]. J Clin Oncol. 2012;30(Suppl):Abstract 539.

Burris HA 3rd, Lebrun F, Rugo HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013;119(10):1908–15.

Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101(17):1174–81.

Jerusalem G, Marinsek N, Ricci J-F, et al. Clinical management and resource utilisation for postmenopausal hormone-receptor-positive HER2-negative (HR+HER2-) advanced breast cancer (BC) in Europe [abstract]. Presented at the 2012 ESMO Congress, September 28–October 2, 2012, Vienna, Austria. Abstract 336P.

Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.

Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011;47(9):1287–98.

Afinitor (everolimus) prescribing information. Revised 2012. Novartis Pharmaceuticals Corporation: East Hanover, NJ. http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf (accessed October 7, 2013).

White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010;182(3):396–403.

Thông tin
Thông tin xuất bản

Advances in Therapy

Tập 30 Số 10

870-884

Thông tin tác giả